Renal involvement in diffuse large B-cell lymphoma: A case report

Yıl 2019, , 144 - 146, 31.10.2019

Sinan Demırcıoglu , Ufuk Telcı Mahsun Ozcelık Ali Dogan İrfan Bayram

https://doi.org/10.5472/marumj.638192

Cited By: 1

Öz

Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma. Approximately 40% of cases have extranodal

involvement. Renal involvement is rare, however, it is associated with poor prognosis. Furthermore, renal involvement increases

the risk of central nervous system (CNS) recurrence. Therefore, it is recommended that CNS prophylaxis should be included in

lymphoma treatment in cases of renal involvement.

Anahtar Kelimeler

Diffuse large B-cell lymphoma, Extranodal, Kidney, Involvement

Kaynakça

• [1] Morgan G, Vornanen M, Puitinen J, et al. Changing trends in the incidence of non-Hodgkin’s lymphoma in Europe. Biomed Study Group. Ann Oncol 1997;8 Suppl 2:49-54.
• [2] Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation—a population-based study of 1575 cases. Br J Haematol 2004;124:151-9.
• [3] Takahashi H, Tomita N, Yokoyama M, et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer 2012;118:4166-72. doi:10.1002/ cncr.27381
• [4] Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica 2011;96:1002-7. doi:10.3324/ haematol.2011.041277
• [5] Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005;23:2797-804. doi:10.1200/JCO.2005.07.155
• [6] Lehners N, Kramer I, Schwarzbich MA, Ho AD, Witzens- Harig M. Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era. Leuk7869
• [7] Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre-and post-rituximab. Ann Hematol 2011;90:809-18. doi:10.1007/s00277.010.1150-7
• [8] Fletcher CD, Kahl BS. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leuk Lymphoma 2014;55:2228-40. doi:10.3109/10428.194.2013.86 9326
• [9] Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010;21:1046-52. doi:10.1093/annonc/mdp432
• [10] Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 2012;23:1267-73. doi:10.1093/annonc/ mdr440
• [11] Tomita N, Takasaki H, Ishiyama Y, et al. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 2015;56:725-9. doi:10.310 9/10428.194.2014.931953
• [12] Ferreri AJ, Bruno-Ventre M, Donadoni G, et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol 2015;168:654-62. doi:10.1111/bjh.13194
• [13] Cheah CY, Seymour JF. Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when? Curr Oncol Rep 2015;17:25. doi:10.1007/s11912.015.0450-4
• [14] Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-16. doi:10.1016/S1470-2045(08)70002-0
• [15] Pfreundschuh M, Trumper L, Osterborg A, et al. CHOPlike chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91. doi:10.1016/S1470-2045(06)70664-7
• [16] Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab- CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 2013;14:525- 33. doi:10.1016/S1470-2045(13)70122-0
• [17] Pfreundschuh M, Poeschel V, Zeynalova S, et al. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non- Hodgkin lymphoma study group. J Clin Oncol 2014;32:4127- 33. doi:10.1200/JCO.2013.54.6861
• [18] Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373- 80. doi:10.1200/JCO.2009.26.2493
• [19] Canet E, Zafrani L, Lambert J, et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One 2013;8:e55870. doi:10.1371/journal.pone.0055870
• [20] Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010;116:2040-5. doi:10.1182/blood-2010-03-276246
• [21] Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117-26. doi:10.1200/JCO.2005.09.131
• [22] Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomized study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12:1013- 22. doi:10.1016/S1470-2045(11)70235-2
• [23] Habermann TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-7. doi:10.1200/JCO.2005.05.1003.
• [24] Howlett C, Snedecor SJ, Landsburg DJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and metaanalysis. Br J Haematol 2015;170:504-14. doi:10.1111/ bjh.13463
• [25] Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013;368:1408-16. doi:10.1056/ NEJMoa1214561
• [26] Hanna F, Prakash A, Allan E, Khalafallah AA. Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin’s lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy. BMJ Case Rep 2018;2018. doi:10.1136/bcr-2017-223637
• [27] Kaur A, Abughanimeh O, Zafar Y, Pluard T. Diffuse large B-cell lymphoma presenting as bilateral renal masses: Successful treatment with dose-adjusted REPOCH (Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) chemotherapy regimen. Cureus 2019;11:e3814. doi:10.7759/cureus.3814